---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-027257"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:34:51.054321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q2 revenue up 151% to $20.5M, raises 2022 guidance to $67M-$75M

## Summary
- Net revenue $20.5M in Q2 2022 vs $8.2M a year ago (+151%); gross margin improved to 70% from 68%.
- Net loss of $11.5M vs $10.7M in Q2 2021; operating expenses rose to $24.1M from $15.5M.
- Entered $60M five-year loan with CIBC, replacing $35M OrbiMed facility; netted $23M cash.
- Full-year 2022 revenue guidance raised to $67M-$75M (prior $59M-$65M), representing 121%-148% YoY growth.
- National OCS Program drove 84% of US revenue; integrated OCS Heart DCD into NOP.

## SEC filing metadata
- accession: 0001564590-22-027257
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/0001564590-22-027257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/tmdx-8k_20220801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-027257
- JSON: https://secwatch.observer/filing/0001564590-22-027257.json
- Plain text: https://secwatch.observer/filing/0001564590-22-027257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.